Navitoclax,Ruxolitinib
abbvie,novartis,incyte
['#mpn', 'navitoclax', 'abbvie']
1l navitoclax + rux trial presented #eha22 by another #mpnlegend #francesco passamonti. 63% svr / 41% symptom response . phase iii data important in defining the role in 1l. 
Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson. Focus- MPNs #MPNSM, Cancer, Health Equity, QoL (Twitter posts = personal opinion)